Sign in
CompletedPhase 2

Linezolid for Syphilis Pilot Study

Key facts

Who runs it
University of Southern California
Where
Chicago, Greensboro, Jackson, and Providence, United StatesSee the 5 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
24 people enrolled
Started
28 Sept 2023
Ended
30 Oct 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Group B, Linezolid 10d
  • Group A, Penicillin
Record updated
4 November 2026

Who can take part

Age
16 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Diagnosed cases of primary, secondary or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment
  • 16 years of age or older
  • Able to provide informed consent/assent
  • Individuals with HIV infection must be on treatment for HIV-infection and virologically suppressed (viral load < 200 copies/mL) or have a CD4 count ≥ 350 cells/mm3 as of their most recent test prior to enrollment

Who cannot take part

  • Participants who receive certain psychotropic medications, e.g., MAO inhibitors, SNRIs, SSRIs
  • Recent (within the past 7 days) or concomitant antimicrobial therapy with activity against syphilis, namely azithromycin, tetracycline, doxycycline, cefixime, ceftriaxone or other beta lactam antibiotics (e.g. amoxicillin)
  • Individuals with known myelosuppressive conditions or receiving myelosuppressive medication
  • Individuals with HIV infection who report HIV treatment interruption for more than 4 weeks since their most recent viral load or CD4 test
  • Individuals with known end renal stage disease, for example individuals in hemodialysis
  • Self-reported allergy to linezolid or penicillin
  • Pregnancy or a positive pregnancy test on the day of enrollment
  • Patients showing signs and symptoms of neurosyphilis
  • Serofast RPR titer, defined as persistently positive RPR titer without more than 4-fold (2-titer level) change for 12 months or greater
  • Individuals weighing 150kg (330 lbs) or more
  • Unwilling or unable to attend follow-up visits

Where in United States

  • Howard Brown HealthChicago, United States
  • Wake Forest Baptist HealthGreensboro, United States
  • Open Arms Healthcare CenterJackson, United States
  • University of Mississippi Medical CenterJackson, United States
  • Open Door HealthProvidence, United States

About the trial

What the trial wants to find out

The study aims to evaluate the efficacy of linezolid for the treatment of syphilis.

The 2 groups in the trial

  • Linezolid 10 DayTreatment being tested

    Oral linezolid 600mg, taken twice a day for 10 days

    Treatment: Group B, Linezolid 10d

  • Benzathine Penicillin GExisting treatment, for comparison

    Single intramuscular injection of 2.4 million units of benzathine penicillin G

    Treatment: Group A, Penicillin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pilot Study of Linezolid for Early Syphilis Treatment
Record updated
4 November 2026